OptimizeRx Shares Tumble 20% After-Hours: Here's Why

OptimizeRx Corp. (NASDAQ:OPRX) shares fell 20.11% to $7.15 in after-hours trading on Wednesday after the company reported third-quarter revenue and adjusted earnings above analyst estimates but lowered its fiscal 2026 revenue guidance.

The healthcare technology company helps life sciences businesses reach and engage healthcare professionals and patients through its technology platform.

Third-Quarter Results

Revenue declined 17% year over year to $21.62 million, but beat the analyst estimate of $21.23 million. Non-GAAP earnings were $0.20 per diluted share, above the estimate of $0.14, representing a 42.9% beat.

GAAP net income was $1.2 million, or $0.06 per diluted share, compared with $0.8 million, or $0.04 per share, a year earlier. Adjusted EBITDA rose 23% to $6.3 million from $5.1 million.

CEO Stephen L. Silvestro said third-quarter adjusted EBITDA exceeded consensus expectations, while the company continued to see lower in-year contracted revenue compared with the prior year.

Updated 2026 Outlook

OptimizeRx lowered its fiscal 2026 revenue guidance to $87 million to $93 million from its previous range of $95 million to $100 million. The company maintained its adjusted EBITDA outlook of $21 million to $25 million.

The company cited lower in-year contracted revenue for the revision, while reporting growth in contracted revenue for 2027 and renewed fourth-quarter spending from a previously significant customer.

Trading Metrics, Technical Analysis

OptimizeRx has a market capitalization of approximately $168.58 million.

The shares have traded between a 52-week high of $16.37 and a 52-week low of $4.54.

Over the past 12 months, shares have fallen 44.58%

Benzinga Edge Stock Rankings indicate positive price trends across short-, medium- and long-term time frames.

Price Action: OptimizeRx shares fell 4.28% to close at $8.95 during Wednesday’s regular trading session.

Photo: Who is Danny/Shutterstock